Please assess the completion status of the following clinical trial:

Trial Title: Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DMD confirmed~* Ambulant~* Corticosteroid therapy for at least one year prior to study day 1 and on a stable dose and schedule for at least 6 months prior to study day 1~* Evidence of muscle weakness by clinical assessment~Exclusion Criteria:~* Any previous treatment with another investigational product within 6 months prior to study day 1~* Any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease that is not related to DMD~* Inability to perform a whole body dual x-ray absorptiometry (DXA) scan

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE-031 0.5 mg/kg q4wk (Type: EXPERIMENTAL): None
- ACE-031 1.0 mg/kg q2wk (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).